This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MCM4 / DNA replication licensing factor MCM4 · IHC design guide
Design Immunohistochemistry for MCM4
Plan chromogenic MCM4 IHC around variable nuclear staining across tissues (HPA tissue IHC). Compare high staining in bone marrow hematopoietic cells with low staining in parathyroid glandular cells (HPA tissue IHC), using the catalog antibody at 2–5 μg/mL (datasheet A02301-1).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
MCM4 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in tissue (HPA tissue IHC) | |
| Staining pattern | Variable nuclear staining across all tissues (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A02301-1) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent between sections. (standard IHC practice; not target-specific) | |
| Caveat | Chromatin association changes as replication progresses (UniProt) | |
| Regulation | Variable expression across tissues (HPA tissue IHC) | |
| Isoform / epitope | No isoforms annotated; one chain spans 2–863 (UniProt) |
Section 1
Recommended MCM4 IHC & IF Protocols
The catalog antibody uses EDTA pH 8.0 heat retrieval (datasheet A02301-1). Three published MCM4 IHC protocols provide tissue-specific settings (PMC10515259; PMC12967608; PMC5250507).
| Sample | Paraffin-embedded mouse colon tissue; fixative not specified (datasheet A02301-1) |
| Fixation | Image fixative and duration unreported (datasheet A02301-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A02301-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A02301-1) |
| Primary antibody | Rabbit anti-MCM4, 2-5μg/ml (datasheet A02301-1) |
| Primary incubation | Overnight at 4 °C (datasheet A02301-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A02301-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | MCM4-positive staining in germinal center cells of appendix (HPA tissue IHC: High). HPA tissue profile: Nuclear expression at variable levels in all tissues. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet A02301-1); the urothelial carcinoma protocol reports pH 9 at 99 °C (PMC10515259).
Section 2
What Is the Expected MCM4 Staining Pattern?
MCM4 is a nuclear, chromatin-associated replication factor with no transmembrane segment (UniProt P33991: location, function, topology). In paraffin-section IHC, expect nuclear staining at variable levels across tissues, including high staining in bone-marrow hematopoietic cells and appendix germinal-center cells (HPA tissue IHC). HPA rates the tissue pattern Enhanced but reports medium consistency between antibody staining and RNA expression; interpret an individual slide with that qualification (HPA tissue IHC).
| Distinct nuclear staining in bone-marrow hematopoietic cells or appendix germinal-center cells (HPA tissue IHC: High). | This fits the reported compartment and cell types (HPA tissue IHC: nuclear expression, High in these cells). Compare nuclei with the counterstain and assess staining in the expected cells, since HPA reports variable levels across tissues (HPA tissue IHC; general IHC practice). |
| Predominantly cytoplasmic, membranous, or extracellular staining with little nuclear signal (UniProt P33991: nuclear/chromosomal location, no transmembrane segment). | That distribution conflicts with the expected MCM4 pattern (UniProt P33991: location; HPA tissue IHC: nuclear expression). Consider nonspecific staining or detection artefact; compare with an appropriate negative control before scoring it as target signal (general IHC practice). |
| Strong staining dominates smooth-muscle cells or soft-tissue chondrocytes (HPA tissue IHC: Low in these cells). | HPA reports low staining in those cell types, so strong staining there deserves scrutiny; low does not mean absent (HPA tissue IHC). Check tissue identity and control staining, then consider cross-reactivity or endogenous detection activity (general IHC practice). |
| Chromogen spreads across nuclei, cytoplasm, and empty tissue spaces without a clear cellular pattern (general IHC practice). | Diffuse background cannot establish MCM4 localisation (general IHC practice). Inspect the negative control and staining distribution; incomplete blocking, excess antibody, or residual detection activity can produce background in chromogenic IHC (general IHC practice). |
| No nuclear signal in bone marrow or appendix where HPA reports high staining in specified cells (HPA tissue IHC). | First confirm that the relevant hematopoietic or germinal-center cells are present (HPA tissue IHC; general IHC practice). Then review the antibody dilution, retrieval, detection reagents, and positive control as general IHC checks; this observation alone does not establish an MCM4-specific fixation effect (general IHC practice). |
💡Expected MCM4 appearanceCall a convincing positive result when defined nuclei stain in the relevant cells, especially cells reported as high in bone marrow or appendix (HPA tissue IHC); diffuse staining outside nuclei is a suspect positive pattern (UniProt P33991: nuclear location; general IHC practice).
| Cellular compartment and replication context (UniProt P33991: location, function). | MCM4 functions in the MCM2–7 and CMG helicase complexes and associates with chromatin before nuclei form, detaching as DNA replication progresses (UniProt P33991). Score the observed nuclear distribution; do not infer replication phase from stain intensity alone (general IHC practice). |
| Tissue and cell-type variation (HPA tissue IHC). | HPA reports variable nuclear expression across tissues, with high staining in bronchial basal cells and breast glandular cells but low staining in liver cholangiocytes and parathyroid glandular cells (HPA tissue IHC). Choose the comparison cell population explicitly when judging intensity (general IHC practice). |
| Antibody evidence (HPA antibody validation; HPA tissue IHC). | HPA004873 and CAB004497 have Enhanced IHC validation; HPA031052 has no listed IHC validation status (HPA antibody validation). HPA nevertheless describes only medium agreement between staining and RNA data, so Enhanced should not be treated as proof that every positive cell is specific (HPA tissue IHC; general IHC practice). |
| Processing and epitope information (UniProt P33991). | UniProt lists no signal peptide, propeptide, transmembrane segment, or glycosylation site, and lists modified residues including phosphorylation (UniProt P33991). These annotations do not identify this antibody’s epitope or establish a retrieval setting or fixation sensitivity; select and verify those conditions using the antibody instructions and controls (general IHC practice). |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected positive cells are present, but their nuclei are unstained (HPA tissue IHC: High in specified bone-marrow and appendix cells). | Possible assay failure or insufficient signal; the slide alone cannot identify which step failed (general IHC practice). | Check the positive control, antibody dilution, retrieval step, and detection reagents, following the IHC-validated antibody’s instructions (general IHC practice). |
| Strong chromogen appears in cells reported as low-staining by HPA (HPA tissue IHC: smooth muscle and chondrocytes Low). | Tissue variation is possible, while cross-reactivity or endogenous detection activity may also contribute (HPA tissue IHC; general IHC practice). | Verify the cell type, examine a negative control, and compare its distribution with the nuclear signal in expected positive cells (general IHC practice; HPA tissue IHC). |
| Cytoplasmic colour is stronger than nuclear colour (UniProt P33991: nuclear/chromosomal location). | The compartment conflicts with the reported MCM4 distribution and may reflect background or nonspecific binding (UniProt P33991; general IHC practice). | Check whether nuclear staining remains distinguishable after reviewing the counterstain and negative control; avoid scoring cytoplasmic colour alone as positive (general IHC practice). |
| Most of the section has diffuse chromogenic haze (general IHC practice). | Background may arise from blocking, antibody concentration, washing, or endogenous detection activity (general IHC practice). | Compare the negative control, then review blocking, dilution, washes, and detection controls under the chosen IHC workflow (general IHC practice). |
| A low-staining reference cell type gives little signal (HPA tissue IHC: Low in parathyroid glandular cells). | Low staining may reflect the reported biological pattern and is a weak basis for declaring assay failure (HPA tissue IHC; general IHC practice). | Judge assay performance against a section containing an expected high cell population, such as bone-marrow hematopoietic cells (HPA tissue IHC; general IHC practice). |
| Q: What localisation should IF/ICC show? (HPA subcellular ICC-IF). | HPA reports the nucleoplasm as MCM4’s main ICC-IF location, with Enhanced localisation evidence (HPA subcellular ICC-IF). | A: Expect nucleoplasmic fluorescence and interpret prominent extranuclear fluorescence cautiously (HPA subcellular ICC-IF; general IF practice). Use the separate IF/ICC guide for assay setup. |
Experiment evidence
IHC & IF images showing MCM4 staining
A02301-1 · IHCIHC analysis of MCM4 using anti-MCM4 antibody (A02301-1). MCM4 was detected in paraffin-embedded section of mouse colon tissue. Heat mediate
A02301-1 · IHCIHC analysis of MCM4 using anti-MCM4 antibody (A02301-1). MCM4 was detected in paraffin-embedded section of rat colon tissue. Heat mediated
A02301-1 · IFIF analysis of MCM4 using anti-MCM4 antibody (A02301-1). MCM4 was detected in immunocytochemical section of A431 cells. Enzyme antigen retri
M02301 · IHCIHC analysis of MCM4 using anti-MCM4 antibody (M02301). MCM4 was detected in a paraffin-embedded section of human colorectal adenocarcinoma
M02301 · IHCIHC analysis of MCM4 using anti-MCM4 antibody (M02301). MCM4 was detected in a paraffin-embedded section of human spleen tissue. Heat mediat
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000104738-MCM4/tissue/cerebral+cortex#imid_1878204
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000104738-MCM4/tissue/colon#imid_1878138
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000104738-MCM4/tissue/liver#imid_1878147
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000104738-MCM4/tissue/kidney#imid_1878148
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA031052; green = MCM4, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA031052; green = MCM4, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for MCM4 IHC & IF
🧪Run appendix first: germinal center cells should show nuclear MCM4 staining (HPA: High in appendix germinal center cells; UniProt P33991: nucleus). HPA detects MCM4 in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and treat cells without nuclear staining on the positive slide as background references rather than validated biological negatives (HPA: no negative rows; HPA: detected in all 45 tissues).
Positive control tissue: Appendix (Germinal center cells, HPA High)
Negative control tissue: None in HPA: MCM4 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show MCM4 in A-431, A-549, U2OS, U-251MG, U2OS, siRNA 1 (10x), U2OS, siRNA 1 (40x), U2OS, siRNA 2 (10x), U2OS, siRNA 2 (40x), U2OS, scrambled (10x), U2OS, scrambled (40x), NIH 3T3, with annotated localisation: Nucleoplasm (enhanced) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only section and a matched rabbit IgG isotype control; use MCM4 knockout material or peptide competition, if available, to test target specificity (caption: rabbit anti-MCM4; standard IHC controls). For appendix sections, quench endogenous peroxidase before DAB detection and check endogenous biotin background with the caption's biotin-based detection method (caption: biotinylated secondary, streptavidin-biotin complex and DAB; standard IHC practice).
⚠️Feasibility: The selected A02301-1 paraffin-section caption does not report a fixative, and the supplied evidence gives no MCM4-specific fixation window or fixation effect (selected-SKU tissue-IHC caption). Heat retrieval in EDTA at pH 8.0 was used in the mouse colon example, but a requirement for that retrieval method has not been established (selected-SKU tissue-IHC caption). ICC-IF images support nucleoplasmic localisation, while the supplied evidence does not establish whether frozen sections or IF are easier than paraffin IHC; assess immune-cell-associated peroxidase and biotin background in appendix controls (HPA: nucleoplasm, enhanced; selected-SKU tissue-IHC caption: biotin-based DAB detection; standard IHC practice).
HPA tissue IHC evidence for MCM4
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Germinal center cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Basal cells | High | Protein (IHC) | HPA → |
| Caudate | Glial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: MCM4 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced MCM4 IHC Tips
Troubleshoot MCM4 chromogenic IHC by checking nuclear staining, tissue preparation, detection background, and scoring against appropriate controls.
What retrieval conditions should I try when MCM4 nuclear staining is weak?
Start with heat-mediated retrieval in EDTA at pH 8.0 (datasheet A02301-1). This is the condition used for the catalog antibody in a paraffin-embedded mouse colon section, followed by 2 µg/mL primary antibody overnight at 4°C (datasheet A02301-1). If nuclear staining remains weak, vary heating and cooling times while holding the buffer and antibody concentration constant; include a positive control section in each run (standard IHC practice). Compare nuclear signal with background rather than increasing retrieval until tissue morphology deteriorates, because MCM4 is expected in the nucleus (UniProt P33991 localisation; HPA: nucleoplasm).
Could fixation explain weak or uneven MCM4 staining?
Target-specific fixation sensitivity is unknown: the catalog image describes a paraffin-embedded section but does not state its fixative (datasheet A02301-1). For chromogenic IHC, document the fixative, fixation duration, section thickness, and processing history before comparing cases, because these variables can change antigen accessibility (standard IHC practice). If staining varies across a batch, process a positive control section alongside it and compare nuclear signal after the same EDTA pH 8.0 retrieval (datasheet A02301-1; standard IHC practice). Do not attribute weak staining to a particular fixative without a controlled comparison; expected MCM4 staining is nuclear (UniProt P33991 localisation).
Where should convincing MCM4 staining appear in a chromogenic section?
Score crisp nuclear staining as the expected pattern: MCM4 is annotated in the nucleus and on chromosomes, while tissue staining is described as nuclear across tissues (UniProt P33991 localisation; HPA: tissue IHC profile). Nucleoplasmic localisation is also supported by cellular imaging (HPA: nucleoplasm, enhanced). Evaluate staining within intact cells and compare neighbouring cell populations, since nuclear intensity can vary with the cell cycle as chromatin association changes during replication (UniProt P33991 localisation and function). Diffuse cytoplasmic DAB without a corresponding nuclear pattern should prompt review of background, tissue preservation, and antibody controls before it is called MCM4 (standard IHC practice; UniProt P33991 localisation).
Could the epitope or MCM4 modification change the IHC result?
The supplied record lists 0 isoforms and identifies a processed chain spanning residues 2–863 (UniProt P33991 isoforms and processing). It also lists N-terminal phosphorylation sites and an MCM C-terminal AAA(+) ATPase domain at residues 441–775 (UniProt P33991 modified residues and domains). Because the catalog antibody’s epitope is not specified here, these annotations cannot establish which modification or domain it recognises (datasheet A02301-1; UniProt P33991). If an unusual staining pattern persists, compare an independently validated antibody with a documented epitope and apply both to matched sections under controlled retrieval conditions (standard IHC practice).
How can IF help assess a questionable MCM4 IHC pattern?
Use IF as a separate localisation check and pair MCM4 with a validated marker for the cell population under study, such as hematopoietic cells when assessing bone marrow (HPA: high in bone marrow hematopoietic cells; standard IF practice). Choose a fluorophore channel away from the section’s strongest autofluorescence, and inspect single-stain and no-primary controls before judging overlap (standard IF practice). MCM4 has no transmembrane segment and is nucleoplasmic, so permeabilise sufficiently for antibody access across the nuclear envelope while preserving nuclear morphology (UniProt P33991 topology; HPA: nucleoplasm; standard IF practice). Treat IF results as corroboration of the expected nuclear IHC pattern, rather than as evidence that the catalog antibody has an IF-validated protocol (HPA: tissue IHC profile; datasheet A02301-1).
How do I distinguish MCM4 staining from chromogenic background?
The catalog example used 10% goat serum blocking, a biotinylated secondary antibody, an avidin–biotin detection complex, and DAB (datasheet A02301-1). For that detection scheme, include no-primary and secondary-only controls, block endogenous peroxidase, and consider endogenous biotin when background follows tissue structures rather than nuclei (standard IHC practice). Check whether excess DAB development or insufficient washing produces diffuse colour, then adjust one variable at a time while retaining the EDTA pH 8.0 retrieval baseline (datasheet A02301-1; standard IHC practice). Genuine MCM4 signal should favour nuclei in viable cells, consistent with its annotated localisation (UniProt P33991 localisation; HPA: tissue IHC profile).
What is a defensible way to quantify MCM4 IHC? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and anatomical region before scoring, then record the percentage of viable nuclei at intensity grades 0–3 (standard IHC practice). An H-score sums each intensity grade multiplied by its percentage of cells, yielding a range of 0–300; alternatively report percent-positive nuclei or positive nuclei per mm² (standard IHC practice). Normalise counts to the number of evaluable nuclei or sampled viable area, and keep thresholds, illumination, and section selection consistent across cases (standard IHC practice). Report cell type separately because MCM4 nuclear expression varies among tissues and cells (HPA: variable nuclear expression across tissues).
When should a positive-looking MCM4 stain be treated cautiously?
A credible positive shows nuclear staining in intact cells, matching MCM4’s nuclear and chromosomal annotation and the reported tissue IHC pattern (UniProt P33991 localisation; HPA: tissue IHC profile). Recheck strong cytoplasmic colour, staining confined to section edges, necrotic areas, or pigment-like deposits against no-primary controls and adjacent preserved tissue (standard IHC practice). With DAB detection, exclude endogenous peroxidase activity and detection-system background before assigning a cell type or positive fraction (datasheet A02301-1: DAB detection; standard IHC practice). Interpret differences between specimens with appropriate controls and cell composition in mind, because the HPA tissue profile reports variable nuclear expression and only medium consistency with RNA data (HPA: tissue IHC profile and reliability).
Boster reagents
Best MCM4 / DNA replication licensing factor MCM4 IHC Antibodies
Anti-MCM4 antibodies have IHC images from paraffin sections of mouse colon and human colorectal adenocarcinoma, plus IF/ICC data from A431 cells (catalog image captions).
Real IHC data
Anti-MCM4 Antibody ®
Cat # A02301-1
Real IHC data
Anti-MCM4 Rabbit Monoclonal Antibody
Cat # M02301
A02301-1 has IHC images from mouse and rat colon, human breast cancer, and human gallbladder adenocarcinoma, plus IF/ICC data from A431 cells (catalog image captions). M02301 has IHC images from human colorectal adenocarcinoma and spleen (catalog image captions).
Which to pick: For human tissue IHC, consider rabbit monoclonal M02301: its paraffin-section image used EDTA retrieval at pH 8.0 and a 1:50 primary dilution (catalog: clone 24M40; M02301 IHC caption). For IF/ICC, choose A02301-1, which lists both applications and has an A431-cell IF image at 5 μg/ml (catalog applications; A02301-1 IF caption). A02301-1 also covers the broadest listed species range for IHC—human, mouse, and rat—with paraffin-section images for each; neither SKU’s IHC caption reports the fixative (catalog reactivity; A02301-1 IHC captions; M02301 IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P33991 (MCM4_HUMAN, DNA replication licensing factor MCM4).
- Human Protein Atlas. MCM4 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. MCM4 subcellular location (ICC-IF): Localized to the nucleoplasm..
- Human Protein Atlas. MCM4 antibody validation summary (3 antibodies).
- MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma. Diagnostic pathology 2023 — PMC10515259.
- Minichromosome maintenance 4 is associated with poor survival and stemness of patients with pancreatic cancer. Medical molecular morphology 2026 — PMC12967608.
- MCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki-67, Bmi1, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions. Human pathology 2016 — PMC5250507.
- Molecular Signature of Small Cell Lung Cancer after Treatment Failure: The MCM Complex as Therapeutic Target. Cancers 2021 — PMC7998124.
- PubMed PMID:7601140 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:9465298 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for MCM4 (DNA replication licensing factor MCM4). Expected localisation Nuclear staining in tissue (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A02301-1). Validated IHC antibody: A02301-1 at 2-5μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Germinal center cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded mouse colon tissue; fixative not specified (datasheet A02301-1); 2. Fixation: Image fixative and duration unreported (datasheet A02301-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A02301-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A02301-1); 8. Primary antibody: Rabbit anti-MCM4, 2-5μg/ml (datasheet A02301-1); 9. Primary incubation: Overnight at 4 °C (datasheet A02301-1). Watch for: Fixation: Keep fixation consistent between sections. (standard IHC practice; not target-specific); Caveat: Chromatin association changes as replication progresses (UniProt); Isoform / epitope: No isoforms annotated; one chain spans 2–863 (UniProt); Regulation: Variable expression across tissues (HPA tissue IHC). Evidence: UniProt P33991, HPA tissue IHC · Enhanced, HPA ICC-IF · nucleoplasm., Datasheet A02301-1, PMC10515259, PMC12967608. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/MCM4/immunohistochemistry-ihc-guide.